Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...
Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of tariffs." ...
The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...
(Bloomberg) -- Merck & Co. shaved the top end of its 2025 revenue guidance and failed to produce any standout sales beats for its medicines in the third quarter, adding to challenges the drugmaker is ...
Merck & Co, known as MSD outside of the USA and Canada, today announced that the European Commission (EC) has approved a new ...
We are honored to introduce KEYTRUDA SC, the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered in one minute every three weeks or in two minutes every six ...
Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-approved indications, the drug is showing it still has unfinished business. In the ...
Industry analyst GlobalData has highlighted the significance of US pharma major Merck's (NYSE: MRK) plan to buy US biotech ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback